New ART Suppresses HIV in Treatment-Experienced Adults

By Marie Rosenthal

High rates of virologic suppression were seen in treatment-experienced adults who switched to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), regardless of preexisting resistance to nucleoside reverse transcriptase inhibitors (NRTIs), according to data presented at CROI 2019. 

BIC/FTC/TAF (Biktarvy, Gilead) is indicated as a single-tablet regimen for HIV-1 infection in treatment-naive adults and to replace the current antiretroviral therapy (ART) in adults